Fulvio Mastrandrea

Summary

Affiliation: Institute of Infectious Diseases and Public Health
Country: Italy

Publications

  1. ncbi The potential role of allergen-specific sublingual immunotherapy in atopic dermatitis
    Fulvio Mastrandrea
    Allergy and Clinical Immunology Operative Unit, AUSL TA1 SS Annunziata Hospital, Taranto, Italy
    Am J Clin Dermatol 5:281-94. 2004
  2. ncbi Sublingual immunotherapy efficacy in patients with atopic dermatitis and house dust mites sensitivity: a prospective pilot study
    Gianni Cadario
    S Giovanni Battista Hospital, Allergy Clinical Immunology, Turin, Italy
    Curr Med Res Opin 23:2503-6. 2007
  3. ncbi Immunotherapy in atopic dermatitis
    F Mastrandrea
    Allergy and Clinical Immunology Centre, A O S S Annunziata, Via Bruno, 74100 Taranto, Italy
    Expert Opin Investig Drugs 10:49-63. 2001
  4. ncbi Methodology and potential pitfalls in allergic diseases study designs: measurements for the assessment of the overall severity of atopic dermatitis--the four step severity score (FSSS), SCORAD-related, electronic system, for the simple and rapid evaluatio
    F Mastrandrea
    Allergy and Clin Immunol CS, SS Annunziata Hospital, Taranto, Italy
    Eur Ann Allergy Clin Immunol 37:357-61. 2005
  5. ncbi CD34+ cells in peripheral blood of healthy human beings and allergic subjects: clue to acute and minimal persistent inflammation
    F Mastrandrea
    Allergy and Clinical Immunology Operative Unit, A O S S Annunziata, Taranto, Italy
    Allergol Immunopathol (Madr) 30:209-17. 2002

Collaborators

  • Gianni Cadario
  • Massimo Milani
  • Michele Pezza
  • Antonella Appino
  • Silvia Pecora
  • Antonia G Galluccio

Detail Information

Publications5

  1. ncbi The potential role of allergen-specific sublingual immunotherapy in atopic dermatitis
    Fulvio Mastrandrea
    Allergy and Clinical Immunology Operative Unit, AUSL TA1 SS Annunziata Hospital, Taranto, Italy
    Am J Clin Dermatol 5:281-94. 2004
    ..Allergen-specific sublingual immunotherapy, given its excellent safety profile and ability to interfere with the systemic aspects of allergic inflammation, appears a good potential candidate for the pathogenetic treatment of the disease...
  2. ncbi Sublingual immunotherapy efficacy in patients with atopic dermatitis and house dust mites sensitivity: a prospective pilot study
    Gianni Cadario
    S Giovanni Battista Hospital, Allergy Clinical Immunology, Turin, Italy
    Curr Med Res Opin 23:2503-6. 2007
    ..Study aim: To evaluate in an open non-controlled, non-randomized pilot trial the effect of SLIT with HDM allergen extracts preparation (SLITone, ALK Abellò Italy) on SCORAD in adult patients with mild-moderate AD...
  3. ncbi Immunotherapy in atopic dermatitis
    F Mastrandrea
    Allergy and Clinical Immunology Centre, A O S S Annunziata, Via Bruno, 74100 Taranto, Italy
    Expert Opin Investig Drugs 10:49-63. 2001
    ..The highly promising sub-lingual immunotherapy (SLIT) is discussed with its potential capability of controlling not only the skin lesion severity but also its capability of preventing the development of atopic dermatitis into asthma...
  4. ncbi Methodology and potential pitfalls in allergic diseases study designs: measurements for the assessment of the overall severity of atopic dermatitis--the four step severity score (FSSS), SCORAD-related, electronic system, for the simple and rapid evaluatio
    F Mastrandrea
    Allergy and Clin Immunol CS, SS Annunziata Hospital, Taranto, Italy
    Eur Ann Allergy Clin Immunol 37:357-61. 2005
    ..The limitations potential generated by a misemployment of medical statistics for clinical trials designed to establish benefits rising from specific immunotherapy for allergic diseases have been also discussed extensively...
  5. ncbi CD34+ cells in peripheral blood of healthy human beings and allergic subjects: clue to acute and minimal persistent inflammation
    F Mastrandrea
    Allergy and Clinical Immunology Operative Unit, A O S S Annunziata, Taranto, Italy
    Allergol Immunopathol (Madr) 30:209-17. 2002
    ....